MedPath

Rest PETCO2 As a Predictor of Post-operative Complications

Recruiting
Conditions
Post-Op Complication
Registration Number
NCT05861089
Lead Sponsor
St. Anne's University Hospital Brno, Czech Republic
Brief Summary

Cardiopulmonary exercise testing (CPET) is considered to be a golden standard in preoperative risk assessment and stratification of high risk patients scheduled for major surgery. However, not all of the patients requiring surgery are willing or able to complete this type of testing.

Vascular surgery patients are predominantly elderly people, with significant comorbidity and high degree of frailty and often can not undergo CPET. In recent years, new parameters with similar prognostic value as standard CPET parameters were studied. Specifically, the partial pressure of end-tidal carbon dioxide (PETCO2) at rest has been shown to have the same prognostic value as ventilatory efficiency.

We hypothesized low PETCO2 at rest will be associated with the development of pulmonary and cardiovascular post-operative complications in patients after major vascular surgery. Accordingly, our aim is to compare PETCO2 measured at rest before surgery in patients who develop post-operative complications and in those who do not.

Detailed Description

Cardiopulmonary exercise testing (CPET) is considered to be a golden standard in preoperative risk assessment and stratification of high risk patients scheduled for major surgery. However, not all of the patients requiring surgery are willing or able to complete this type of testing. Moreover, inability to perform CPET has been linked with inferior outcomes following surgery.

Vascular surgery patients are predominantly elderly people, with significant comorbidity and high degree of frailty. Therefore, CPET as a mean of risk stratification would be of an especial interest in this group of patients. However, vascular surgery patients often present with peripheral arterial disease, which may contribute to early leg ischemia during exercise and therefore invalid cardiorespiratory reserve function measurement.

In recent years, new parameters with similar prognostic value as standard CPET parameters were studied. Specifically, the partial pressure of end-tidal carbon dioxide (PETCO2) at rest has been shown to have the same prognostic value as ventilatory efficiency in the prediction of post-operative complications in lung resection surgery patients. Whether the same parameter can be used to predict postoperative complications in a different sub-set of surgical patients (i.e. vascular surgery patients) is yet to be determined.

We hypothesized low PETCO2 at rest will be associated with the development of pulmonary and cardiovascular post-operative complications in patients after major vascular surgery. Accordingly, our aim is to compare PETCO2 measured at rest before surgery in patients who develop post-operative complications and in those who do not.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
130
Inclusion Criteria
  • indication for major vascular surgery (aortobifemoral bypass surgery)
Exclusion Criteria
  • tracheostomy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
post-operative complicationsfirst 30-post operative days

cardiovascular complications

pulmonary complicationsfirst 30-post operative days

post-operative complications

Secondary Outcome Measures
NameTimeMethod
hospital length of stayup to 30 days

hospital length of stay

intensive care unit length of stayup to 30 days

intensive care unit length of stay

mortalityfrom the first 30-post operative days

mortality

Trial Locations

Locations (1)

St. Anne's University Hospital in Brno

🇨🇿

Brno, Czech Republic, Czechia

St. Anne's University Hospital in Brno
🇨🇿Brno, Czech Republic, Czechia
Ivan Cundrle, MD, PhD
Contact
+420543182553
cundrle@fnusa.cz
Adam Predac, MD
Contact
+420543182553
adam.predac@fnusa.cz
Robert Staffa, MD, PhD
Contact
Robert Vlachovsky, MD, PhD
Contact
Martin Ferkodic, MD
Contact

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.